Pricing Log in Create free account
Saturday 17 October 2026 Export BIIB’s income statement to Excel — free account

Biogen Inc.

BIIB Healthcare Drug Manufacturers General

Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.

232.65 2.70 −1.15%
Market cap
$34.8B
P/E
41.0×
Fwd P/E
31.5×
Dividend yield
—
F-score
4/9
Altman Z
3.13
Beneish M
−2.67
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Biogen Inc. 10-Q filed Jul 29, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 6:36 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 31, 2025: 121 added · 114 removed · 103 modified; 29 with only figures updated; 3 moved without change

338 more changes in this Item, word by word, in Powerpack.

Powerpack